ArticleEuropean journal of epidemiology2026
Genetic risk score to enhance glaucoma case detection: a prospective double-blind screening study (EyeLife) in the population-based Lifelines cohort.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Early detection of glaucoma prevents blindness but its low population-based prevalence impedes cost-effective screening. We investigated whether genetic pre-screening could increase the prior probability. Design, methods, and primary analysis were pre-specified and published previously. In this prospective study, we invited 1829 participants aged 55 + from the Dutch Lifelines cohort, selecting from either the highest or lowest 20% of a GWAS-based genetic risk score distribution; subgroups had similar age and gender. Researchers were blinded to subgroup allocation; participants to genetic risk selection. Participants underwent perimetry, optical coherence tomography, fundus photography, tonometry, pachymetry, and visual acuity assessment. Abnormalities prompted a full ophthalmic examination. Participants were classified as definite, probable, or possible open-angle glaucoma, or as unaffected. We calculated the relative risk of combined definite and probable glaucoma for high versus low genetic risk, adjusting for age, sex, and genotyping platform. 1022 participants (median [interquartile range] age 64 [59-70] years, 53% female, Northwestern European ancestry) agreed to participate and were included, 487 with high and 535 with low genetic risk. Of these, 59 (age 70 [64-76] years) were classified as definite (29 with high and 2 with low genetic risk) or probable (21 and 7) glaucoma. Relative risk was 7.4 (95% confidence interval 3.7-14.7), indicating that participants with high genetic risk were over seven times more likely to be classified with glaucoma than those with low risk. Stratifying the general population based on genetic risk strongly increases the prior probability of glaucoma and may enable a cost-effective screening approach.
Indexed as
Identifiers
42400736What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.